CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
CDT Equity Inc. (CDT)
Company Research
Source: GlobeNewswire
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced the filing of two new patent applications that further expand the Company’s intellectual property portfolio surrounding tapinarof, a drug currently approved for the treatment of psoriasis and atopic dermatitis. The first newly filed patent covers a combination therapy pairing tapinarof with a class of drugs clinically proven in psoriasis and atopic dermatitis, while the second patent relates to novel cocrystal forms of tapinarof with these agents. CDT believes these developments may underpin a second-generation tapinarof product with enhanced formulation properties and potential efficacy benefits, creating an opportunity to extend the asset’s lifecycle and broaden its clinical and commercial scope for current stakeholders. The combination approach may also enable entry into disease areas not previously addressable by tapinarof alone,
Show less
Read more
Impact Snapshot
Event Time:
CDT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDT alerts
High impacting CDT Equity Inc. news events
Weekly update
A roundup of the hottest topics
CDT
News
- CDT Equity Inc. Announces Reverse Stock SplitGlobeNewswire
- CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing StrategyGlobeNewswire
- CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth [Yahoo! Finance]Yahoo! Finance
- CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of GrowthGlobeNewswire
- CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence [Yahoo! Finance]Yahoo! Finance
CDT
Sec Filings
- 3/25/26 - Form 8-K
- 3/18/26 - Form 8-K
- 3/9/26 - Form 8-K
- CDT's page on the SEC website